HC Wainwright & Co. : The G1 Therapeutics (GTHX.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $9.00.
Buy Rating Affirmed: G1 Therapeutics' Cosela Shows Significant Survival Benefits in MTNBC
G1 Therapeutics Analyst Ratings
Buy Rating Affirmed for G1 Therapeutics Amid Promising Clinical Outcomes
Analysts Offer Insights on Healthcare Companies: Personalis (PSNL) and G1 Therapeutics (GTHX)
Strategic Licensing Agreements and Revenue Forecast Uphold Buy Rating for G1 Therapeutics
HC Wainwright & Co. : The G1 Therapeutics (GTHX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
G1 Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on G1 Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. : The G1 Therapeutics (GTHX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
G1 Therapeutics Analyst Ratings
Optimistic Buy Rating for G1 Therapeutics Amidst Solid Financial Footing and Cosela's Market Expansion
G1 Therapeutics: A Buy Rating on Promising Trials and Robust Financial Outlook
G1 Therapeutics Analyst Ratings
Needham Reiterates Buy on G1 Therapeutics, Maintains $12 Price Target
Buy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment Appeal
Needham: Reiterates G1 Therapeutics (GTHX.US) rating and adjusted from buy to buy rating, target price is $12.00.
G1 Therapeutics Analyst Ratings
Needham Reiterates Buy on G1 Therapeutics, Maintains $12 Price Target
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Palatin Technologies (PTN) and G1 Therapeutics (GTHX)
No Data